Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Brazil / NCT06917794
Enrolling by invitation Observational

Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project

NCT06917794 · tracked via the Priya Life Science Brazil tracker
Sponsor
D'Or Institute for Research and Education
Phase
Observational
Started
2025-03-14
Last updated
2025-04-08

Condition(s) studied

Colo-rectal CancerPolygenic Risk ScoreSomatic MutationHereditary CancerGermline MutationsCancer Predisposition Syndrome

Study summary

Development of a polygenic risk score based on somatic and germline genetic information from patients with colorectal cancer

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * \> 18 years; * Histologically confirmed diagnosis of colorectal cancer; * Have available tumor material for somatic sequencing, obtained from biopsy or routine surgery; * Sign the informed consent form (ICF) for the study. Exclusion Criteria: • Pregnants

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
Instituto D'Or de Pesquisa e Ensino Fortaleza Ceará
CPOC - Centro de Pesquisa Oncológica e Clínica, faz parte do Complexo Associação Obras Sociais lrmã Dulce (AOSID) Salvador Estado de Bahia
Instituto D'Or de Pesquisa e Ensino Salvador Estado de Bahia
Instituto D'Or de Pesquisa e Ensino Brasília Federal District
Instituto D'Or de Pesquisa e Ensino Curitiba Paraná
Instituto D'Or de Pesquisa e Ensino Recife Pernambuco
Instituto D'Or de Pesquisa e Ensino Rio de Janeiro Rio de Janeiro
Instituto D'Or de Pesquisa e Ensino São Paulo São Paulo
Instituto do Câncer do Estado de São Paulo São Paulo São Paulo

More D'Or Institute for Research and Education trials in Brazil

Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote Starting soon
TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC Recruiting
Encouraging Positive Parenting Habits Recruiting
Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment Starting soon

Other trials for the same condition

Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy Recruiting
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06917794 on ClinicalTrials.gov ↗ ← All trials in Brazil